Skip to main content

Table 2 Characteristics of subjects included in the sputum study

From: The association between airway eosinophilic inflammation and IL-33 in stable non-atopic COPD

 

Healthy Non-smokers

Healthy Smokers

COPD

Number of subjects

20

20

40

Sex (M/F)

10/10

11/9

22/18

Age (years)

56.84±2.14

57.85±2.00

67.40±1.12a†

Pack-years

0

32.14±2.96

41.99±2.78

Time since diagnosis (years)

7.05±1.00

PB FEV1% of predicted

101.9±2.92

96.88±6.26

61.98±2.76a†

PB FEV1%FVC

77.69±1.43

74.39±1.18

52.49±1.57a†

BMI (kg/m2)

27.23 ± 0.80

27.72 ± 0.68

28.39 ± 1.05

CAT score

15.8 ± 1.18

6MWT (m)

388.6 ± 11.08

mMRC score

1 (0–3)

BODE index

1 (0–6)

Current smokers (%)

0

100

42.5

Use of ICS (%)

0

0

0

No. of atopic subjects (No)

0

0

0

Sputum eosinophils (%)

0.89 ± 0.28

1.43 ± 0.28

2.93 ± 0.95

Sputum neutrophils (%)

18.89 ± 3.77

23.28 ± 2.23

37.40 ± 4.93a

Sputum macrophages (%)

65.69 ± 3.76

56.85 ± 1.99

44.70 ± 41a#

Sputum lymphocytes (%)

6.43 ± 0.84

4.26 ± 0.72

6.60 ± 1.99

Sputum eosinophils (No of cells/ g of sputum × 104)

1.60 ± 0.77

1.55 ± 0.73

2.70 ± 1.33

Sputum neutrophils (No of cells/ g of sputum ×104)

14.95 ± 3.12

19.40 ± 10.01

19.50 ± 7.36

Sputum macrophages (No of cells/ g of sputum ×104)

16.10 ± 2.79

31.00 ± 5.62

41.98 ± 12.55

Sputum lymphocytes (No of cells/ g of sputum ×104)

2.60 ± 0.47

2.10 ± 0.45

5.92 ± 3.25

  1. PB post bronchodilator, FEV 1 forced expiratory volume in first second, FVC forced vital capacity, CAT COPD assessment test, 6MWT six-minute walk test, mMRC modified Medical Research Council dyspnea scale, ICS inhaled corticosteroids
  2. aCOPD vs Healthy Non-smokers, p < 0.05; COPD vs Healthy Smokers p < 0.05; median (min-max)